Eli Lilly’s Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults

 Eli Lilly’s Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults

IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library

Shots:

  • The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies
  • P-III RA-BEACON study results: ACR20 (49% vs 27%) physical function based on the Health Assessment Questionnaire Disability Index (HAQ-DI) before/ after treatment (1.71, 1.78/ 1.31, 1.59)
  • Olumiant (baricitinib, 2mg) is an oral drug indicated for patients with RA who have inadequate response to TNF antagonist therapies and is approved in 50 countries including the US, EU and Japan. In Dec,2009 Lilly and Incyte collaborated to develop and commercialize Olumiant for inflammatory and autoimmune diseases

Click here to read full press release/ article | Ref: Eli Lilly | Image: WSJ

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post